Cargando…

Plasmodium falciparum drug resistance in Angola

Facing chloroquine drug resistance, Angola promptly adopted artemisinin-based combination therapy as the first-line to treat malaria. Currently, the country aims to consolidate malaria control, while preparing for the elimination of the disease, along with others African countries in the region. How...

Descripción completa

Detalles Bibliográficos
Autores principales: Fançony, Cláudia, Brito, Miguel, Gil, Jose Pedro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4746923/
https://www.ncbi.nlm.nih.gov/pubmed/26858018
http://dx.doi.org/10.1186/s12936-016-1122-z
_version_ 1782414894843297792
author Fançony, Cláudia
Brito, Miguel
Gil, Jose Pedro
author_facet Fançony, Cláudia
Brito, Miguel
Gil, Jose Pedro
author_sort Fançony, Cláudia
collection PubMed
description Facing chloroquine drug resistance, Angola promptly adopted artemisinin-based combination therapy as the first-line to treat malaria. Currently, the country aims to consolidate malaria control, while preparing for the elimination of the disease, along with others African countries in the region. However, the remarkable capacity of Plasmodium to develop drug resistance represents an alarming threat for those achievements. Herein, the available, but relatively scarce and dispersed, information on malaria drug resistance in Angola, is reviewed and discussed. The review aims to inform but also to encourage future research studies that monitor and update the information on anti-malarial drug efficacy and prevalence of molecular markers of drug resistance, key fields in the context and objectives of elimination.
format Online
Article
Text
id pubmed-4746923
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-47469232016-02-10 Plasmodium falciparum drug resistance in Angola Fançony, Cláudia Brito, Miguel Gil, Jose Pedro Malar J Review Facing chloroquine drug resistance, Angola promptly adopted artemisinin-based combination therapy as the first-line to treat malaria. Currently, the country aims to consolidate malaria control, while preparing for the elimination of the disease, along with others African countries in the region. However, the remarkable capacity of Plasmodium to develop drug resistance represents an alarming threat for those achievements. Herein, the available, but relatively scarce and dispersed, information on malaria drug resistance in Angola, is reviewed and discussed. The review aims to inform but also to encourage future research studies that monitor and update the information on anti-malarial drug efficacy and prevalence of molecular markers of drug resistance, key fields in the context and objectives of elimination. BioMed Central 2016-02-09 /pmc/articles/PMC4746923/ /pubmed/26858018 http://dx.doi.org/10.1186/s12936-016-1122-z Text en © Fançony et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Fançony, Cláudia
Brito, Miguel
Gil, Jose Pedro
Plasmodium falciparum drug resistance in Angola
title Plasmodium falciparum drug resistance in Angola
title_full Plasmodium falciparum drug resistance in Angola
title_fullStr Plasmodium falciparum drug resistance in Angola
title_full_unstemmed Plasmodium falciparum drug resistance in Angola
title_short Plasmodium falciparum drug resistance in Angola
title_sort plasmodium falciparum drug resistance in angola
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4746923/
https://www.ncbi.nlm.nih.gov/pubmed/26858018
http://dx.doi.org/10.1186/s12936-016-1122-z
work_keys_str_mv AT fanconyclaudia plasmodiumfalciparumdrugresistanceinangola
AT britomiguel plasmodiumfalciparumdrugresistanceinangola
AT giljosepedro plasmodiumfalciparumdrugresistanceinangola